NCT06246643 2026-03-19
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
Bayer
Phase 2 Active not recruiting
Bayer
Amgen
Incyte Corporation
Exelixis
Suzhou Suncadia Biopharmaceuticals Co., Ltd.